The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?
Sanofi looks compelling with strong fundamentals and a robust pipeline. Click for this updated look at SNY stock and why I ...
AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 b | AbbVie has struck a deal to buy Apogee Therapeutics for $10 ...
AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent ...
AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, its largest buyout in more than five years ...
AbbVie said on Monday it would buy Apogee Therapeutics for $10.9 billion, the company's largest buyout in more than five ...
Recently published Chronic Spontaneous Urticaria Market Insights report includes a comprehensive understanding of current ...
The pipeline includes clinical and IND stage mono and multispecific antibodies that target immune-mediated inflammatory diseases.
June 22 (Reuters) - AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, in its largest buyout ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results